The results indicated that glycolysis markers, including PKM2, STMN1, MCT4, GLUT1, HK-2, CA9, and GLUT2, can serve as potential prognostic biomarkers and therapeutic targets for liver cancer. This evidence concerns the gene SLC2A1 and liver cancer.